Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trials

BACKGROUND: Patients undergoing chemotherapy are known to be at risk for infection from myelosuppression by cytotoxic agents (CTAs) or immunosuppressive effects from mTOR inhibitors. The infection risk of newly developed anticancer agents has not been fully evaluated. It remains unknown how T-cell a...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:ESMO Open
Main Authors: Fujiwara, Yutaka, Kuchiba, Aya, Koyama, Takafumi, Machida, Ryunosuke, Shimomura, Akihiko, Kitano, Shigehisa, Shimizu, Toshio, Yamamoto, Noboru
Format: Artigo
Jezik:Inglês
Izdano: BMJ Publishing Group 2020
Teme:
Original Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7174012/
https://ncbi.nlm.nih.gov/pubmed/32276948
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2019-000653
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki